CENTOGENE N.V.

CNTG
Delayed Quote. Delayed  - 07/28 04:00:00 pm
11.48USD -0.95%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Other Biotechnology & Medical Research
Centogene BV is a Germany-based company engaged in the rare disease market. It focuses on transforming clinical, genetic and biochemical data into medical solutions for patients, physicians and pharmaceutical companies. The Company provides the full spectrum of methods and technology for human genetics analysis. It develops a rare disease platform based on its real-world data repository with over 2.0 billion weighted data points from over 450,000 patients representing around 115 different, which includes epidemiologic, phenotypic and genetic data that reflects a global population, as well as a biobank of patients’ blood samples. In addition, it is active in the research and development products for human genetics. The Company operates in Germany and the United States.

Number of employees : 657 people.
Sales per Business
2020
COVID-19101.8369.6%
Diagnostics25.2017.2%
Pharmaceutical19.3213.2%
USD in Million
Sales per region
2020
Germany92.4163.1%
United States21.7314.8%
Middle East14.399.8%
Netherlands7.505.1%
Europe7.335%
Latin America2.151.5%
Asia Pacific0.610.4%
North America0.230.2%
USD in Million
Managers
Name Title
Andrin Oswald Chief Executive Officer
René Just Managing Director & Chief Financial Officer
Peer Michael Schatz Chairman-Supervisory Board
Volkmar Weckesser Chief Information Officer
Philip Lambert Chief Scientific Officer
Michael Dost Senior Director-Information Technology Operations
Krishna Kumar Kandaswamy Director-Research & Development Bioinformatics
Florian Vogel Senior Vice President-Clinical Lab Operations
Christoph de Artiagoitia Senior Vice President-Finance & Administration
Hubert Birner Independent Member-Supervisory Board
Shareholders
Name Equities %
DPE Deutsche Private Equity GmbH 6,036,287 26.9%
Eric Souêtre 2,947,594 13.1%
TVM Capital GmbH 2,489,748 11.1%
Arndt Rolfs 2,239,612 9.99%
Equicore Beteiligungs GmbH 1,497,962 6.68%
Michael Schlenk 487,109 2.17%
Goldman Sachs Asset Management LP 447,219 1.99%
Hans Bodo Hartmann 445,537 1.99%
Holger Friedrich 350,145 1.56%
Federated Global Investment Management Corp. 324,939 1.45%
Sector Other Biotechnology & Medical Research
1st jan.Capi. (M$)
CENTOGENE N.V.7.51%260
MODERNA, INC.214.44%131 902
LONZA GROUP AG20.01%55 520
IQVIA HOLDINGS INC.35.73%46 608
CELLTRION, INC.-27.16%31 131
SEAGEN INC.-17.54%26 209
PHARMARON BEIJING CO., LTD.70.75%21 498
CUREVAC N.V.-35.40%21 497
ALNYLAM PHARMACEUTICALS, INC.35.87%20 757
HANGZHOU TIGERMED CONSULTING CO., LTD-0.54%20 084
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.57.19%19 737
BIO-TECHNE CORPORATION49.14%18 419
INCYTE CORPORATION-11.12%16 789
PPD, INC.34.28%16 137
NOVAVAX, INC.60.53%13 261
ICON PUBLIC LIMITED COMPANY14.71%11 845
QIAGEN N.V.-2.21%11 796
PRA HEALTH SCIENCES, INC.0.00%10 965
INTELLIA THERAPEUTICS, INC.143.33%9 617
CRISPR THERAPEUTICS AG-23.30%9 409
SYNEOS HEALTH, INC.28.96%9 078